Open Access

MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma

  • Authors:
    • Gang Han
    • Yan Wang
    • Wenzhi Bi
    • Jinpeng Jia
    • Wei Wang
  • View Affiliations

  • Published online on: December 30, 2014     https://doi.org/10.3892/etm.2014.2161
  • Pages: 679-684
  • Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNA‑124 (miR‑124) has been demonstrated to be downregulated in numerous human malignancies and correlated with tumor progression. However, its expression and clinical significance in osteosarcoma remains unclear. Thus, the aim of the present study was to explore the effects of miR‑124 in osteosarcoma tumorigenesis and development. Using reverse transcription‑quantitative polymerase chain reaction, miR‑124 expression was detected in primary osteosarcoma tissues and osteosarcoma cell lines. The correlation of miR‑124 expression with clinicopathological factors and prognosis was statistically analyzed. MTT, flow cytometric, and Transwell invasion and migration assays were used to test the proliferation, apoptosis, invasion and migration of osteosarcoma cells transfected with miR‑124 mimic. It was found that the expression levels of miR‑124 in osteosarcoma tissues were significantly lower than those in corresponding noncancerous bone tissues (P<0.001). In addition, miR‑124 downregulation more frequently occurred in osteosarcoma specimens with advanced clinical stage (P<0.001), positive distant metastasis (P=0.005) and poor response to neoadjuvant chemotherapy (P=0.013). Univariate and multivariate analysis identified low miR‑124 expression as an unfavorable prognostic factor for overall survival. Furthermore, transfection of miR‑124 mimic into MG63 cells was able to reduce cell proliferation, invasion and migration, and promote cell apoptosis. These findings indicate that miR‑124 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for the molecular therapy of osteosarcoma.

Introduction

Osteosarcoma is the most common primary bone tumor in adolescents and young adults (1). Despite progress in therapeutic technologies, including surgery, chemotherapy, radiotherapy and biological therapy, the overall survival (OS) of patients with osteosarcoma remains unsatisfactory. Approximately 80% of patients will eventually develop local relapse or metastatic disease following surgical treatment (2), and pulmonary metastasis is the major cause of fatal outcome (3). Like other malignancies, the development of osteosarcoma is a multistep process with accumulation of genetic and epigenetic changes. However, to date, the highly complex molecular mechanisms underlying its initiation and progression are poorly understood. Therefore, it is necessary to search for novel markers for osteosarcoma, which can accurately identify the biological characteristics of tumors, improve therapeutic strategies and predict clinical outcome.

MicroRNAs (miRNAs) are single-stranded, small noncoding RNAs of 18–25 nucleotides in length (4). They can negatively regulate gene expression through base-pairing to the 3′ untranslated region (3′UTR) of target messenger RNA (mRNA), resulting in translation inhibition or mRNA degradation (5,6). Beyond involvement in diverse biological processes, including cell growth, apoptosis, development, differentiation and endocrine homeostasis (7), emerging evidence strongly suggests that the deregulation or dysfunction of miRNAs contributes to human carcinogenesis and cancer progression (810). miRNAs can function as either oncogenes or tumor suppressors according to the roles of their target genes. In terms of osteosarcoma, in vitro functional assays have shown that miR-126 and miR-133b inhibit the proliferation, invasion and migration of osteosarcoma cells (11,12). Clinical analysis has demonstrated that decreased miR-145 and increased miRNA-214 expression levels in osteosarcoma are associated with advanced clinical stage and poor prognosis (13,14). Furthermore, Zhou et al reported that the upregulation of miR-33a promoted the chemoresistance of MG63 cells to cisplatin (15). These findings indicate that miRNAs may act not only as diagnostic and prognostic markers, but also as potential therapeutic targets of human osteosarcoma.

One of the cancer-related miRNAs is miR-124. It was first reported to be highly expressed in neuronal cells, where it regulates neuronal development and neural plasticity (16). Subsequent studies revealed that miR-124 may modulate the process of tumorigenesis and the behavior of cancer cells. It has been corroborated to be downregulated and exert tumor suppressive function in medulloblastoma (17), breast cancer (18), ovarian cancer (19), cervical cancer (20), gastric cancer (21), colorectal cancer (22), hepatocellular carcinoma (23), pancreatic cancer (24) and prostate cancer (25). However, the expression and function of miR-124 in osteosarcoma is largely unknown. In the current study, miR-124 expression was investigated in paired osteosarcoma and adjacent noncancerous bone tissues by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. The correlation of miR-124 levels with clinicopathological factors and prognosis was also statistically analyzed. Furthermore, the effects of miR-124 on malignant phenotypes of osteosarcoma cells were elucidated.

Materials and methods

Patients and tissue samples

This study was approved by the Research Ethics Committee of General Hospital of PLA, (Beijing, China). Written informed consent was obtained from all patients. All specimens were handled and made anonymous according to ethical and legal standards.

A total of 105 primary osteosarcoma and corresponding noncancerous bone tissue samples were collected from the General Hospital of PLA (Beijing, China) for RT-qPCR analysis between March 2002 and February 2008. No patients had previously received a blood transfusion, chemotherapy or radiotherapy. All patients underwent neoadjuvant chemotherapy and wide resection of the tumor. Tumor biopsies were collected prior to neoadjuvant chemotherapy and were fresh-frozen and stored at −80°C. The patient information is summarized in Table I. Clinical tumor stage was classified according to the Enneking staging system (26). Tumor response to pre-operative chemotherapy was assessed using the Huvos grading system (27), on the basis of tumor necrosis in the resected specimen. Good response indicated ≥90% tumor necrosis and poor response indicated <90% tumor necrosis. All of the patients were followed up periodically. The OS time was defined as the time from primary surgery to mortality of the patient or, for living patients, the date of last follow-up.

Table I

Correlation of miR-124 expression with clinicopathological features of osteosarcoma.

Table I

Correlation of miR-124 expression with clinicopathological features of osteosarcoma.

miR-124 expression

Clinicopathological featuresNumber of casesHigh n (%)Low n (%)P-value
Age
 <25 years4521 (46.7)24 (53.3)0.322
 ≥25 years6032 (53.3)28 (46.7)
Gender
 Male5726 (45.6)31 (54.4)0.329
 Female4827 (56.3)21 (43.7)
Tumor size
 >8 cm5523 (41.8)32 (58.2)0.079
 ≤8 cm5030 (60.0)20 (40.0)
Anatomical location
 Tibia/femur6429 (45.3)35 (54.7)0.231
 Elsewhere4124 (58.5)17 (41.5)
Serum level of lactate dehydrogenase
 Elevated6936 (52.2)33 (47.8)0.501
 Normal3617 (47.2)19 (52.8)
Serum level of alkaline phosphatase
 Elevated7137 (52.1)34 (47.9)0.680
 Normal3416 (47.1)18 (52.9)
Clinical stage
 IIA4639 (84.8)7 (15.2)<0.001
 IIB/III5914 (23.7)45 (76.3)
Distant metastasis
 Absent7444 (59.5)30 (40.5)0.005
 Present319 (29.0)22 (71.0)
Response to chemotherapy
 Good4031 (77.5)9 (22.5)0.013
 Poor6522 (33.8)43 (66.2)

[i] miR-124, microRNA-124.

Cell culture

Four human osteosarcoma cell lines (MG63, U2OS, Saos-2 and SW1353) and a human normal osteoblastic cell line hFOB 1.19 were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (Invitrogen Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin in humidified air at 37°C with 5% CO2.

RNA extraction and RT-qPCR

Total RNA was isolated using TRIzol® reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. Reverse transcription reaction was carried out using 10 ng total RNA, 50 nmol/l stem-loop RT primer, 1X RT buffer (TIANGEN Biotech Co., Ltd., Beijing, China), 0.25 mmol/l each deoxynucleotide triphosphate (Sigma-Aldrich, Beijing, China), 3.33 U/μl MultiScribe reverse transcriptase (Sigma-Aldrich) and 0.25 U/μl RNase inhibitor (Sigma-Aldrich). The 7.5 μl reaction mixture was initially incubated at 16°C for 30 min, 42°C for 30 min and 85°C for 5 min, and then maintained at 4°C. qPCR was performed using the standard TaqMan MicroRNA assays protocol on an ABI 7500 Real-Time PCR detection system (Applied Biosystems by Life Technologies, Foster City, CA, USA), with cycling conditions of 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. U6 small nuclear RNA was used as an internal control. The RT primers were 5′-GTC GTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGAT ACGACGGCATTCT-3′ for miR-124 and 5′-TGGTGT CGTGGAGTCG-3′ for U6. The PCR primers for mature miR-124 or U6 were designed as follows: miR-124 forward, 5′-GATACTCATAAGGCACGCGG-3′ and reverse, 5′-GTGCAGGGTCCGAGGT-3′. U6 forward, 5′-CTCGCTTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCACGAATTTGCGT-3′. The threshold cycle (Ct) was defined as the fractional cycle number at which the fluorescence passed the fixed threshold. Each sample was measured in triplicate, and the relative amount of miR-124 to U6 was calculated using the equation 2−ΔCt, where ΔCT = (CTmiR–124 − CTU6).

Cell transfection

For RNA transfection, the cells were seeded into each well of 96-well plate and incubated overnight, then transfected with either miR-124 mimic or negative control (NC) (TIANGEN Biotech Co., Ltd.) using Lipofectamine 2000 (Invitrogen Life Technologies) following the manufacturer’s instructions. The sequences of NC were nonhomologous to any human genome sequences, and were used to eliminate potential nonsequence-specific effects. At 48 h after transfection, cells were harvested for further experiments.

Cell proliferation assay

Cell proliferation capacity was evaluated with an MTT assay. Cells were seeded into 96-well culture plates at a density of 2,000 cells in 200 μl/well and incubated at 37°C for 24 h, after transfection. Then, 100 μl MTT solution (0.5 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) was added to each well, and the cells were incubated for another 4 h. The medium was then replaced with 150 μl DMSO. Spectrometric absorbance at 490 nm was measured using a Multilabel Counter microplate reader (Safire; Tecan Austria GmbH, Grödig, Austria). Cell proliferation was assessed daily for four consecutive days, and the MTT assay was repeated three times.

Detection of apoptosis by flow cytometry

Apoptosis was detected by flow cytometric analysis. Briefly, the cells were washed and resuspended in 0.5 ml phosphate-buffered saline (pH 8.0) at a concentration of 1×106 cells/ml. Then, the cells were stained with Annexin V and propidium iodide (PI), using the Annexin V Apoptosis Detection kit (TIANGEN Biotech Co., Ltd.). After incubation at room temperature in the dark for 15 min, the cell apoptosis was analyzed on a FACSC LSR II (Becton Dickinson and Co., San Jose, CA, USA).

Cell migration and invasion assays

The migration and invasion assays were performed using 24-well Transwell chambers (8 μm; Corning Inc., Corning, NY, USA). For the migration assay, 1×105 cells suspended in 200 μl serum-free RPMI-1640 medium were seeded into the upper chamber of the Transwell invasion system, and 500 μl RPMI-1640 medium containing 10% FBS was added to the lower chamber. Following a 24-h-incubation, cells on the upper surface of the membrane were scrubbed off, and the migrated cells were fixed with 95% ethanol and stained with 0.1% crystal violet for 10 min. The number of migrated cells was determined by counting five random fields on each membrane. The invasion assay protocol was similar to that of the migration assay, with the exception that the upper chambers were first covered with 1 mg/ml Matrigel.

Statistical analysis

SPSS software, version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are shown as the mean ± standard deviation (SD). The differences between groups were analyzed using the Student’s t-test or Chi-square test. Patient survival and their differences were determined by the Kaplan-Meier method and log-rank test. A Cox’s regression model was used for univariate and multivariate analysis. P<0.05 was considered to indicate a statistically significant result.

Results

Decreased expression of miR-124 in osteosarcoma cell lines and primary tumor samples

The expression levels of miR-124 in osteosarcoma tissues, corresponding noncancerous bone biopsy samples, osteosarcoma cell lines and the human normal osteoblastic cell line hFOB 1.19 were detected by RT-qPCR and normalized to U6 small nuclear RNA. As shown in Fig. 1A, the results revealed that miR-124 expression levels were significantly lower in osteosarcoma tissues (8.3±2.1) than in the corresponding noncancerous bone tissues (19.6±4.2; P<0.001). Decreased miR-124 expression was also observed in osteosarcoma cell lines compared with that in hFOB 1.19 cells (Fig. 1B; P<0.001). The MG63 cell line, which possessed the lowest levels of miR-124 expression among all tested osteosarcoma cell lines, was selected for analysis in further experiments.

miR-124 expression and clinicopathological features in osteosarcoma

The correlations of miR-124 expression with various clinicopathological parameters of osteosarcoma tissues are summarized in Table I. Using the median miR-124 expression in all 105 osteosarcoma patients as a cutoff, the patients were divided into a high miR-124 expression group and a low miR-124 expression group. As shown in Table I, miR-124 was significantly downregulated in patients with osteosarcoma of advanced Enneking stage (P<0.001), positive distant metastasis (P=0.005) and poor response to neoadjuvant chemotherapy (P=0.013). No significant difference was observed between miR-124 expression levels and patient age, gender, tumor size, anatomical location, or the serum levels of lactate dehydrogenase and alkaline phosphatase.

Correlation between miR-124 expression and prognosis of osteosarcoma patients

Whether miR-124 expression has prognostic potential for the OS of osteosarcoma patients was investigated. Using the Kaplan-Meier method and log-rank test, the OS times of patients with low miR-124 expression levels were found to be significantly shorter than those of patients with high miR-124 expression levels (P=0.005; Fig. 2). In addition, survival benefits were also found in those with smaller tumor size (P=0.034), lower Enneking stage (P<0.001), without metastasis (P=0.011) and a better response to preoperative chemotherapy (P=0.006). Multivariate Cox regression analysis including the aforementioned significant parameters revealed that miR-124 expression [relative risk (RR) 6.325; P=0.015], clinical stage (RR 8.973; P=0.008), metastasis status (RR 3.576; P=0.032), and response to preoperative chemotherapy (RR 4.728; P=0.022) were independent prognostic markers (Table II).

Table II

Univariate and multivariate analysis of overall survival in 105 patients with osteosarcoma.

Table II

Univariate and multivariate analysis of overall survival in 105 patients with osteosarcoma.

VariablesUnivariate log-rank test (P)Cox multivariable analysis (P)Relative risk
MiR-124 expression (high vs. low)0.0050.0156.325
Clinical stage (IIA vs. IIB/III)<0.0010.0088.973
Distant metastasis (absent vs. present)0.0110.0323.576
Tumor size (>8 cm vs. ≤8 cm)0.034--
Response to chemotherapy (good vs. poor)0.0060.0224.728

[i] miR-124, microRNA-124.

Effects of miR-124 on cell proliferation, apoptosis, invasion and migration

As shown in Fig. 3A, the expression level of miR-124 in the miR-124 mimic-transfected cells was significantly higher compared with that in NC-transfected cells (P<0.01). The MTT assay demonstrated that transfection with miR-124 mimic reduced the proliferation of MG63 cells (Fig. 3B). In addition, promotion of cell apoptosis was also observed in the miR-124 mimic-transfected cells (Fig. 3C). Furthermore, Transwell invasion and migration assays showed a significant reduction in invaded or migrated MG63 cell numbers following miR-124 transfection (Fig. 3D). These results indicate that miR-124 is involved in the negative regulation of osteosarcoma cell growth, invasion and migration in vitro.

Discussion

Dysregulation of miRNAs has been demonstrated to be involved in tumorigenesis and progression in various types of tumor; however, the elucidation of their potential roles in osteosarcoma remains in the early stage of development. In the current study, it was first demonstrated that miR-124 was downregulated in osteosarcoma cell lines and primary tumor samples. Low levels of miR-124 expression were found to be correlated with aggressive clinicopathological features and unfavorable to survival. Furthermore, the transfection of miR-124 mimic into MG63 cells was able to reduce cell proliferation, invasion and migration, and promote cell apoptosis in vitro. To the best of the authors’ knowledge, this is the first study regarding the clinical significance and functional attributes of miR-124 in osteosarcoma.

Previous research has reported the tumor suppressive function of miR-124 in numerous human malignancies. In vitro, ectopic miR-124 expression inhibits cell growth and induces apoptosis in gastric cancer (21), colorectal cancer (22), pancreatic cancer (24), prostate cancer (28) and cervical cancer (20). The upregulation of miR-124 also reduces cell invasion and migration in ovarian cancer (19), pancreatic cancer (24), hepatocellular carcinoma (23) and breast cancer (18). In addition, miR-124 radiosensitizes human glioma cells (29). In vivo, Zhang et al revealed decreased miR-124 expression and its association with high tumor grade (Dukes C and D) in colorectal cancer (22). Liang et al identified that low miR-124 levels correlated with poor differentiation of breast cancer (18). Zheng et al observed that miR-124 downregulation occurred more frequently in hepatocellular carcinoma patients with large tumor size, multiple tumor nodes and advanced tumor stage (23). Moreover, lower expression levels of miR-124 indicated worse prognosis of patients suffering from pancreatic cancer, colorectal cancer or hepatocellular carcinoma (23,24). In xenotransplanted models, miR-124-treated nude mice exhibited smaller tumor sizes and lower tumor weights in comparison with those in the control group (21,22,24,28). These findings suggest that miR-124 might play an important role not only in tumor initiation and progression but also in the molecular-targeted therapy of human malignancies.

The mechanism by which miR-124 expression affects carcinogenesis and cancer development is complex. Some useful targets have been identified during the past few years, including SphK1 (19), STAT3 (22), SLC16A1 (17), Rac1 (24), ROCK2 (23), EZH2 (23), Slug (18), the androgen receptor (28) and CDK4 (29). However, there is no ‘one-to-one’ connection between miRNAs and target mRNAs. An average miRNA can have more than 100 targets (30). Conversely, several miRNAs can converge on a single transcript target (31). Thus, the potential regulatory circuitry afforded by miR-124 may be enormous, and the identification of the complex molecular network involved in its function remains an important subject for future investigation.

In conclusion, the results of the present study revealed that miRNA-124 was downregulated in osteosarcoma cell lines and clinical samples. Low-level expression of miR-124 was significantly associated with a more aggressive and poor prognostic phenotype of patients. Restored miR-124 expression in MG63 cells exhibited antitumor effects in vitro. These data suggest an important role of miR-124 in the molecular etiology and gene therapy of osteosarcoma.

References

1 

Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Eppert K, Wunder JS, Aneliunas V, Kandel R and Andrulis IL: von Willebrand factor expression in osteosarcoma metastasis. Mod Pathol. 18:388–397. 2005. View Article : Google Scholar

4 

Osman A: MicroRNAs in health and disease - basic science and clinical applications. Clin Lab. 58:393–402. 2012.

5 

Zhao G, Cai C, Yang T, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI

6 

Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar

9 

Dieckmann KP, Spiekermann M, Balks T, et al: MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 107:1754–1760. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Takahashi M, Cuatrecasas M, Balaguer F, et al: The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI

11 

Yang C, Hou C, Zhang H, et al: miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci. 15:423–437. 2014. View Article : Google Scholar : PubMed/NCBI

12 

Zhao H, Li M, Li L, et al: MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar

13 

Wang Z and Cai H, Lin L, Tang M and Cai H: Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatr Blood Cancer. 61:206–210. 2014. View Article : Google Scholar

14 

Tang M, Lin L, Cai H, Tang J and Zhou Z: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther. 6:833–838. 2013.PubMed/NCBI

15 

Zhou Y, Huang Z, Wu S, et al: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI

16 

Chandrasekar V and Dreyer JL: microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol Cell Neurosci. 42:350–362. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Li KK, Pang JC, Ching AK, et al: miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol. 40:1234–1243. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Liang YJ, Wang QY, Zhou CX, et al: MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 34:713–722. 2013. View Article : Google Scholar :

19 

Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI

20 

Wilting SM, van Boerdonk RA, Henken FE, et al: Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 9:1672010. View Article : Google Scholar : PubMed/NCBI

21 

Xia J, Wu Z, Yu C, et al: miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 227:470–480. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Zhang J, Lu Y, Yue X, et al: MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One. 8:e703002013. View Article : Google Scholar : PubMed/NCBI

23 

Zheng F, Liao YJ, Cai MY, et al: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289. 2012. View Article : Google Scholar

24 

Wang P, Chen L, Zhang J, et al: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 33:514–524. 2014. View Article : Google Scholar

25 

Shi XB, Xue L, Ma AH, et al: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 32:4130–4138. 2013. View Article : Google Scholar

26 

Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 106–120. 1980.PubMed/NCBI

27 

Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 49:1221–1230. 1982. View Article : Google Scholar : PubMed/NCBI

28 

Chen X, Chen J, Gan S, et al: DNA damage strength modulates a bimodal switch of p53 dynamics for cell-fate control. BMC Biol. 11:732013. View Article : Google Scholar : PubMed/NCBI

29 

Deng X, Ma L, Wu M, et al: miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol. 114:263–274. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Brennecke J, Stark A, Russell RB and Cohen SM: Principles of microRNA-target recognition. PLoS Biol. 3:e852005. View Article : Google Scholar : PubMed/NCBI

31 

Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March-2015
Volume 9 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Han G, Wang Y, Bi W, Jia J and Wang W: MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma. Exp Ther Med 9: 679-684, 2015.
APA
Han, G., Wang, Y., Bi, W., Jia , J., & Wang, W. (2015). MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma. Experimental and Therapeutic Medicine, 9, 679-684. https://doi.org/10.3892/etm.2014.2161
MLA
Han, G., Wang, Y., Bi, W., Jia , J., Wang, W."MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma". Experimental and Therapeutic Medicine 9.3 (2015): 679-684.
Chicago
Han, G., Wang, Y., Bi, W., Jia , J., Wang, W."MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma". Experimental and Therapeutic Medicine 9, no. 3 (2015): 679-684. https://doi.org/10.3892/etm.2014.2161